OncoPharm

John Bossaer

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

  1. Perioperative Enortumab vedotin + Pembrolizumab

    HACE 4 D

    Perioperative Enortumab vedotin + Pembrolizumab

    The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future. Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

    17 min
  2. Axi-Cel and 5-FU Label Changes

    12 FEB

    Axi-Cel and 5-FU Label Changes

    We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

    13 min

  3. 5 FEB

    Core Communication Skills in Chemotherapy Education

    A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *Agenda Setting *Information Management *Active Listening *Addressing Feelings *Common Ground

    15 min
  4. PATINA

    29 ENE

    PATINA

    Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

    16 min
  5. Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    22 ENE

    Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

    18 min
  6. Oncology Drug Use Evolution

    15 ENE

    Oncology Drug Use Evolution

    This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time. Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

    11 min
  7. 2025 New Drug Review

    8 ENE

    2025 New Drug Review

    A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

    15 min
  8. Bladder Cancer Updates & SC Amivantamab

    18/12/2025

    Bladder Cancer Updates & SC Amivantamab

    Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data. Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

    13 min
Ver todo (415)

Información

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Ficha técnica

  • Creado por
    John Bossaer
  • Años en activo
    2017 - 2026
  • Episodios
    415
  • Clasificación
    Apto
  • Derechos de autor
    © All rights reserved
  • Sitio web del podcast
    OncoPharm

Quizá también te guste